Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Stjernschantz

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biophysical Journal|June 2, 2010
Improved ligand-protein binding affinity predictions using multiple binding modesEva Stjernschantz, Chris Oostenbrink
Expert Opinion on Drug Metabolism & Toxicology|May 20, 2008
Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450Eva Stjernschantz, Nico P E Vermeulen, Chris Oostenbrink
International Journal of Molecular Sciences|December 20, 2013
CYP 2D6 binding affinity predictions using multiple ligand and protein conformationsLovorka Perić-Hassler, Eva Stjernschantz, Chris Oostenbrink, et al.
Journal of Medicinal Chemistry|December 12, 2003
Improving structure-based virtual screening by multivariate analysis of scoring dataMicael Jacobsson, Per Lidén, Eva Stjernschantz, et al.
Journal of Chemical Information and Modeling|September 26, 2006
Are automated molecular dynamics simulations and binding free energy calculations realistic tools in lead optimization? An evaluation of the linear interaction energy (LIE) methodEva Stjernschantz, John Marelius, Carmen Medina, et al.
Molecular and Cellular Endocrinology|December 23, 2009
Comparison of murine and human estrogen sulfotransferase inhibition in vitro and in silico--implications for differences in activity, subunit dimerization and substrate inhibitionEva Stjernschantz, Jelle Reinen, Walter Meinl, et al.
Journal of Medicinal Chemistry|February 3, 2007
Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesisBarbara M A van Vugt-Lussenburg, Eva Stjernschantz, Jeroen Lastdrager, et al.
Proteins|October 25, 2007
Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3Eva Stjernschantz, Barbara M A van Vugt-Lussenburg, Alois Bonifacio, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biophysical Journal|June 2, 2010
Improved ligand-protein binding affinity predictions using multiple binding modesEva Stjernschantz, Chris Oostenbrink
Expert Opinion on Drug Metabolism & Toxicology|May 20, 2008
Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450Eva Stjernschantz, Nico P E Vermeulen, Chris Oostenbrink
International Journal of Molecular Sciences|December 20, 2013
CYP 2D6 binding affinity predictions using multiple ligand and protein conformationsLovorka Perić-Hassler, Eva Stjernschantz, Chris Oostenbrink, et al.
Journal of Medicinal Chemistry|December 12, 2003
Improving structure-based virtual screening by multivariate analysis of scoring dataMicael Jacobsson, Per Lidén, Eva Stjernschantz, et al.
Journal of Chemical Information and Modeling|September 26, 2006
Are automated molecular dynamics simulations and binding free energy calculations realistic tools in lead optimization? An evaluation of the linear interaction energy (LIE) methodEva Stjernschantz, John Marelius, Carmen Medina, et al.
Molecular and Cellular Endocrinology|December 23, 2009
Comparison of murine and human estrogen sulfotransferase inhibition in vitro and in silico--implications for differences in activity, subunit dimerization and substrate inhibitionEva Stjernschantz, Jelle Reinen, Walter Meinl, et al.
Journal of Medicinal Chemistry|February 3, 2007
Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesisBarbara M A van Vugt-Lussenburg, Eva Stjernschantz, Jeroen Lastdrager, et al.
Proteins|October 25, 2007
Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3Eva Stjernschantz, Barbara M A van Vugt-Lussenburg, Alois Bonifacio, et al.
Pageof 1